Experience with the Use of Botulinum Toxin Type a in Patients With Neurogenic Bladder Due to Spinal Dysrraphism.
DOI:
https://doi.org/10.54212/27068048.v7i2.57Keywords:
Onabotulinumtoxin, Neurogenic Bladder, Spinal DysrraphismAbstract
Objective: Describe the main clinical and urodynamic findings in patients with neurogenic bladder managed with botulinum toxin.
Materials and methods: A retrospective observational study was conducted in a single center with a clinical record review, urodynamic studies and images of patients with neurogenic bladder, comparing findings before and after the application of onabotulinumtoxin A.
Results: Onabotulinumtoxin A was placed on an outpatient basis in 36 patients, in pediatric patients between 3 and 15 years, a dose of 10 IU / Kg with a maximum dose of 200 IU; without reporting major postoperative complications. All patients affected neurogenic bladder secondary to spinal dysrraphism and had been given management with antimuscarinics and intermittent catheterization.
Within the clinical findings, we observed decreased leakage between catheterizations after application. In the urodynamics we observed an increase in cystometric capacity, a decrease in detrusor pressure at maximum capacity, with escape to higher volumes with statistical significance in the mentioned variables.
Conclusions: Onabotulinumtoxin A injections significantly improved not only clinical symptoms, but also urodynamic parameters in patients with neurogenic bladder secondary to spinal dysrraphism. This is a simple technique, with minimal adverse effects and is generally well tolerated.
Downloads
References
Sturm, R., & Cheng, E. (2016). The Management of the Pediatric Neurogenic Bladder. Curr Bladder Dysfunct Rep, 225-233.
https://doi.org/10.1007/s11884-016-0371-6 DOI: https://doi.org/10.1007/s11884-016-0371-6
Kroll, P. (2019). The Current Role of Botox in a Pediatric Neurogenic. Current Bladder Dysfunction Reports, 115-123.
https://doi.org/10.1007/s11884-019-00516-9 DOI: https://doi.org/10.1007/s11884-019-00516-9
Madersbacher H (1990). The various types of neurogenic bladder dysfunction:. Paraplejia, 217-29.
https://doi.org/10.1038/sc.1990.28 DOI: https://doi.org/10.1038/sc.1990.28
Sager, y col. (2016). Rol de OnabotulinumtoxinA en el tratamiento. Medicina Infantil, 101-107.
Metcalfe, P y col. (2006). What is the need for additional bladder surgery after bladder augmentation in childhood? J Urol, 1801 - 1805. https://doi.org/10.1016/j.juro.2006.03.126 DOI: https://doi.org/10.1016/j.juro.2006.03.126
Husmann DA (2017). Mortality following augmentation cystoplasty: a transitional urologist's viewpoint. J Pediatr Urol, 358.
https://doi.org/10.1016/j.jpurol.2017.05.008 DOI: https://doi.org/10.1016/j.jpurol.2017.05.008
Figueroa y col. (2014). Singlecenter experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children. Journal of Pediatric Urology., 368-373. https://doi.org/10.1016/j.jpurol.2013.10.011 DOI: https://doi.org/10.1016/j.jpurol.2013.10.011
Gamè y col. (2009). Botulinum Toxin-A (Botox) intradetrusor inyeccions in children with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic iterature review. J Ped Urol. , 156-164. https://doi.org/10.1016/j.jpurol.2009.01.005 DOI: https://doi.org/10.1016/j.jpurol.2009.01.005
Pascali y col. (2011). Effects of botulinum toxin type A in the bladder wallof children with neurogenic bladder dysfunction: a comparison of histological features before and after injections. J Urol., 2552-7. https://doi.org/10.1016/j.juro.2011.01.019 DOI: https://doi.org/10.1016/j.juro.2011.01.019
Riccabona y col. (2004). Botulinum-A toxin injection into the detrusor: a safe alternative into the treatment of children with myelomeningocele. J Urol, 845-848. https://doi.org/10.1097/01.ju.0000108892.35041.2d DOI: https://doi.org/10.1097/01.ju.0000108892.35041.2d
Austin, y col.. (2016). The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Update Report From the Standardization Committee of the International Children's Continence Society. Neurourology and Urodynamics , 35:471-481. https://doi.org/10.1002/nau.22751 DOI: https://doi.org/10.1002/nau.22751
Schulte-Baukloh H, M. T. (2002). Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: Preliminary results. Urology, 325-8. https://doi.org/10.1016/S0090-4295(01)01641-7 DOI: https://doi.org/10.1016/S0090-4295(01)01641-7
Radmayr y col. (2019). Paediatric urology. EAU Guidelines, 49 -54.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Celeste Alston, Carlos Marín, Alejandro Jiménez, Jorge Castro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
